> Shares in PharmaMar crashed after the Spanish biotech revealed a phase 3 ovarian cancer trial had missed its primary endpoint. Synthetic tetrahydroisoquinoline alkaloid Zepsyre failed to improve progression-free survival in patients with platinum-resistant ovarian cancer. Statement (PDF)
> Ablynx named Robert Friesen, Ph.D., as its CSO. Friesen joins from ProQR at a time when Ablynx is the subject of takeover interest from Novo Nordisk. Release
> BioCanCell unveiled plans to list its stock in the U.S. The Israeli biotech revealed its IPO intentions in a statement about the pricing of a $25 million (€20 million) financing round. Statement
> Advicenne followed up on its IPO by appointing Linda Law, M.D., to oversee its U.S. clinical trial activities. Release
> Genfit kicked off its pediatric NASH program. Statement
> ImmuPharma raised £10 million ($14 million). Release